Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Slides:

Advertisements

Similar presentations

Cancer and the Cell Cycle : An overview Ken Wu. Disclaimer This tutorial is a simple and conceptual guide to the cancer module and the cell cycle If there.

Advertisements

Signal Transduction Mechanisms Underlying Underlying Growth Control and Oncogenesis Ronit Sagi-Eisenberg Dept. of Cell and Developmental Biology Sackler.

Avances en el tratamiento del Cáncer de Pulmón Lugar de la Angiogénesis en el tratamiento de segunda linea del CPCNP Carlos Camps Inducing angiogenesis.

Medical Genetics & Genomics Guri Tzivion, PhD Extension 506 BCHM 560: January 2015 Windsor University School of Medicine.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Structural Basis for Ligand- Receptor Recognition and Dimerization Moosa Mohammadi Dept. of Pharmacology Medical Science Building, 4th Floor, Rooms 425,

2) From the cell membrane to the nucleus

Lecture 11: Signalling for Life/Death 1)Describe the eukaryotic cell cycle and the purpose of checkpoints. 2)Describe the role of cyclins and cyclin-dependent.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Lecture 23 Signal Transduction 2

New Perspectives in Cancer Therapy Óren Smaletz Programa de Oncologia Hospital Israelita Albert Einstein.

Northern England Strategic Clinical Network Conference Thyroid Sub-group Update Dr Sath Nag Consultant Endocrinologist Vice Chair, Thyroid NSSG South Tees.

Ligand Receptor Cortisol Receptor is located in the cytosol Retinoid Receptors are in the nucleus Target gene in the nucleus Regulation of Transcription.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Growth Factors, Receptors, and Signal Transduction I

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.

Signal Transduction II Transduction Proteins & Second Messengers.

BIOL 5190/6190 Cellular & Molecular Singal Transduction

Vecchi e nuovi “targets”, vecchi e nuovi farmaci

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Biological and Molecular Targeted Therapy for HHC

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.

Cancer --an Overview  Cell Division  Hormones and Cancer  Malignant Transformation  Angiogenesis and Metastasis  Growth.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg) Louis M. Weiner, MD Lombardi Comprehensive Cancer Center Georgetown.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Underlying Principles and Future Targets for Molecular Therapy of SCCHN Prof. Tim H. Brümmendorf Dept. of Hematology and Oncology University Hospital Eppendorf.

1 Hepatocellular Carcinoma Overview of Hepatocellular Carcinoma Epidemiology.

Growth Factors, Receptors,

Signal Transduction I Receptors & Ligands. Signal Transduction.

How to present a scientific paper Dr. Rebecca B. Riggins Department of Oncology, Georgetown University

Compensatory Angiogenesis and Tumor Refractoriness Prof. Rajesh N Gacche Tumor Biology Laboratory, School of Life Sciences SRTM Univeristy, Nanded, India.

ANGIOGENESIS Vasculogenesis: Embryonic development from endothelial precursors called ‘angioblasts’ Angiogenesis/ neovascularization: Process of blood.

Basic Science of Surgical Oncology

Signal transduction: receptor gene

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

Negative regulation of cell cycle by intracellular signals Checkpoint p53 detects DNA damage & activates p21 p21 inhibits cdk2-cyclinA Intracellular Regulation.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Integrin-EGFR Cross-Activation Elizabeth Brooks Department of Chemical Engineering University of Massachusetts, Amherst Peyton Lab Group Meeting December.

Lee S. Rosen, MD Premiere Oncology, California Affiliated with the John Wayne Cancer Institute and St John’s Health Center Santa Monica, California Multitargeted.

Angiogenesis in rheumatologic disorders. New blood vessels De novo formation Formation from pre existing vessels Endothelial formation from mesenchymal.

Samsung Genome Institute Samsung Medical Center

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Trans. Vis. Sci. Tech ;5(2):10. doi: /tvst Figure Legend:

Inducing Angiogenesis

Underlying Mechanisms for Distant Metastasis - Molecular Biology

Miriam Marqués, Francisco X. Real European Urology

Fas NF-κB JNK Bcl-2 Akt p21 Bax Ras TRAILR p53 EGFR TRADD Myc TNFR

Figure 1 A schematic representation of the HER2 signalling pathway

ET-1 acting via ETAR promotes:

Keratinocyte Apoptosis in Epidermal Development and Disease

Nat. Rev. Urol. doi: /nrurol

Vascular Endothelial Growth Factor (VEGF) Pathway

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

Tumor-Associated Macrophages: From Mechanisms to Therapy

SRC and STAT Pathways Journal of Thoracic Oncology

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Platelet-derived growth factor (PDGF) signalling pathway.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

Presentation transcript:

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University of Pécs and at the University of Debrecen Identification number: TÁMOP /1/A

SIGNALLING IN TUMOR CELLS Tímea Berki and Ferenc Boldizsár Signal transduction Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University of Pécs and at the University of Debrecen Identification number: TÁMOP /1/A

TÁMOP /1/A Immune selection in the development of cancer: no two tumors are alike Initiation, proliferation, diversification Microevolution, selection of immune resistance Immune escape and unchecked proliferation

TÁMOP /1/A Tumor and activated T cells Activated T cell Immune escape Tumor cell DF3/MUC1 CD28 CTLA4 B7-1/2 MHC ITCR Growth arrest Proliferation Cell death RCAS1R Cytokine receptors Cytokines RCAS1 FasLDcR3 FasFasL

TÁMOP /1/A What happens when Fas- stimulated immune cells resist to die? Tissue environment? Cytokines? FasFasL Tumor cells Immune cells

TÁMOP /1/A TGF-  signaling in tumor signaling and cancer progression Tumor cellStromal cell Latent TGF-  ActiveTGF-  Proteases Thrombospondin Integrins Proteases Thrombospondin Integrins Decorin Betaglycan Decorin Betaglycan Effects on tumor cells Growth inhibition (early) Invasion (late) Effects on tumor environment Stroma ↑ Proteases ↑ ECM production Endothelial cells ↑ Angiogenesis Immune cells ↓ Fas-L activity ↓ NK cells ↓ T cells ↓ B cells

TÁMOP /1/A Fas signal PKC MAPK FasL FADD CAP3 c- FLIP AIF TPA Death substrates Type II Type I Fas Caspase-8 Caspase-3 tBid Cytc Caspase-9 Cytc Apaf -1 Bcl- 2 Bcl-xL Caspase-8 APOPTOSIS DISC

TÁMOP /1/A Growth factors (GFs) Small molecular weight soluble mediators They control: 1 1Proliferation 2 2Survival 3 3Metabolism 4 4Tissue differentiation Important implication in tumors Cytokines – growth factors

TÁMOP /1/A Receptor tyrosine kinase (RTK) families 90 unique Tyr kinases in the human genome, 58 are RTKs Growth factor, cytokine and hormone receptors Classes: I – EGFR family (ErbB) X – LTK family II – Insulin rec. family XI – TIE family III – PDGF familyXII – ROR family IV – FGF familyXIII – DDR family V – VEGF familyXIV – RET family VI – HGF family (c-Met) XV – KLG family VII – Trk familyXVI – RYK family VIII – Eph familyXVII – MuSK family IX – AXL family

TÁMOP /1/A GF signaling pathwaysTranscription RTK Ligand P P P P P P P P Dimerization Src PKC PLC STAT JAK Akt

TÁMOP /1/A GF receptors as therapeutic targets PDGF-C Cell survival Proliferation Apoptosis resistance Metastasis Angiogenesis P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P EGFRHer2Her3Her4VEGFR1VEGFR2VEGFR3PDGFR-aPDGFR-bc-kit EGF TGF  β-cellulin Amphiregulin HB-EGF No specific ligands Heregulins β-cellulin NRG2 NRG3 VEGF-BVEGF-AVEGF-CVEGF-DPDGF-A PDGF-B PDGF-D SCF SOS GRB2 Ras Rac Rho CDC42 MEK1/2 Erk Raf ERK pathway MKK4/7 JNK MEKK JNK pathway MKK3/6 p38 Tak p38 pathway Akt mTor PI3K Everolimus Imatinib Trastuzumab Leflunomide Lapatinib Gefitinib Erlotinib Panitumumab Sorafenib Cetuximab Bevacizumab Vandetanib Sunitinib Enzastaurin Pazopanib Motesanib Midostaurin Temsirolimus Sirolimus P P P P P P P P

TÁMOP /1/A HER gene family HER1/EGFR(1): ligands known (TNF , EGF etc), kinase activity HER2/EGFR2: no ligand, kinase activity HER3/EGFR3: ligands known (TNF , EGF etc), no kinase activity HER4/EGFR4: ligands known, kinase activity Characteristic: Characteristic: co-operations

TÁMOP /1/A HER2 genetics in cancer HER2mutationamplification Breast cancer: DICEC-delp95+ Gastric cancer+ Ovarian cancer+ Endometrian cancer+

TÁMOP /1/A Anti-EGFR resistance in NSCLC EGFR resistance mutation 790M K-RAS mutation C-MET amplification EGFR negativity (protein?)

TÁMOP /1/A Colorectal cancer and EGFR EGFR expression (mRNS and protein): 75-80% Intensity variable (1-100% cell) EGFR amplification: % Chr. 7 polisomy: 30% Chr.7 LOH: 8% (loss) TK-mutation: 12% (only Asia) EC-LD R497K polimorphism SP1-216 promoter G/T polimorphism

TÁMOP /1/A VEGFR2 receptor signaling in endothelial cells P P P P P P P P P P P P P P P P VEGFR1VEGFR2VEGFR3 P P P P P P P P VEGF-BVEGF VEGF-C VEGF-D SOS GRB2 Ras Raf MEK TSAd PLC  PKC Erk eNOS Src Akt PI3K Ca 2+ Caspase-9 Bad Cell survival Cell migration Angiogenesis Monocyte migration Lymphangiogenesis Vascular permeability Cell proliferation VEGF-E

TÁMOP /1/A Kinase inhibitory profiles of anti-angiogenic agents KIT Angioblast FLT3 Angioblast VEGFR1 Blood vessel VEGFR2 Blood vessel VEGFR3 Lymph vessel PDGFR Pericyte FGFR1 Blood vessel EGFRMET Gleevec Sunitinib Sorafenib PTK AG GW ZD ZD Döme, Tímár, AntiCancer Agents, 2007

TÁMOP /1/A Overview of EGF signaling